Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) mutations are commonly administered to EGFR-positive lung cancer patients. However, resistance to EGFR-TKIs (mostly gefitinib and erlotinib) is presently a significant problem. Limited studies have fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, E., Wu, Feng, Guo, Mengfei, Yin, Zhengrong, Li, Yumei, Li, Minglei, Xia, Hui, Deng, Jingjing, Yang, Guanghai, Jin, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751970/
https://www.ncbi.nlm.nih.gov/pubmed/36530971
http://dx.doi.org/10.3389/fonc.2022.1008283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751970/
https://www.ncbi.nlm.nih.gov/pubmed/36530971
http://dx.doi.org/10.3389/fonc.2022.1008283

Ejemplares similares